The therapeutic use of DYRK1A-mediated cell cycle regulation was recently extended to other diseases, such as diabetes and myocardial infarction, as DYRK1A inhibition was found to sustain pancreatic beta cells and cardiomyocytes growth11–16. The gene discussed is DYRK1A; the disease is myocardial infarction.